Clinical Trial Highlights

• One-Year Results from the AMPLE Study
• The ASTIS Trial: First Results
• 24-Week Results from the RAPID-PsA Study
• Efficacy and Safety of NNC0109-0012 (Anti-IL-20 mAb) in Patients with RA: Results from a Phase 2a Trial
• 24-Week Data from the Phase 4 ADACTA Trial
• Efficacy of Different Doses of Rituximab for the Treatment of RA: Data from the CERERRA Collaboration
• Anti-TNF Therapy and CV Risk in RA
• 12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA
• Naïve to Biologic Therapy or Inadequate Responders to TNF-α Inhibitors: A Phase 2 Study of LY2439821
• LITHE Study Subset: Identification of Tocilizumab Early Response-Associated Biomarkers
• Adalimumab Plus Methotrexate versus Methotrexate Monotherapy in Early RA
• Results from the ESPOIR Cohort Study
• 2-Year Results from the GO-RAISE Trial
• Clinical and Radiological Outcomes of Four DAS ≤2.4 Targeted Treatment Strategies: Eight-Year Results from the BeSt Study
• Inflammation and Fatty Degeneration in New Bone Formation in Patients with AS Treated with Anti-TNF Agents
• Lung Ultrasound for Screening Interstitial Lung Disease